Telix and SHINE partner for Lutetium-177 Supply
10 févr. 2022 16h09 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a new global clinical supply agreement with...
Telix Expands Lutetium-177 Network with Eckert & Ziegler Clinical Supply Agreement
08 févr. 2022 17h27 HE
|
Telix Pharmaceuticals Limited
MELBOURNE and LIEGE, Belgium, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a global clinical supply agreement with Berlin-based...
First Patient Dosed in ProstACT Program for Prostate Cancer Therapy
26 janv. 2022 16h51 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in the Company’s...
Telix Expands Prostate Cancer Activity with GenesisCare Collaboration
18 août 2021 18h47 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today releases details of two ancillary studies under the ProstACT program...
Telix and Monrol Expand Alliance to Include Lutetium Supply
10 mai 2021 18h57 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and ISTANBUL, Turkey, May 10, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered a global clinical supply...
Telix Commences Phase III Clinical Trial of Prostate Cancer Therapy
09 mai 2021 19h13 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, May 09, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has been granted Human Research Ethics Committee (HREC)...